Total Payments
$16,593
2024 Payments
$397.59
Companies
12
Transactions
97
Medicare Patients
3,092
Medicare Billing
$286,331
Payment Breakdown by Category
Other$11,107 (66.9%)
Consulting$2,298 (13.8%)
Food & Beverage$1,796 (10.8%)
Travel$1,391 (8.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $8,426 | 3 | 50.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,681 | 2 | 16.2% |
| Consulting Fee | $2,298 | 1 | 13.8% |
| Food and Beverage | $1,796 | 89 | 10.8% |
| Travel and Lodging | $1,391 | 2 | 8.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Dexcom, Inc. | $14,475 | 10 | $0 (2022) |
| Novo Nordisk Inc | $1,177 | 69 | $0 (2024) |
| W. L. Gore & Associates, Inc. | $424.52 | 1 | $0 (2018) |
| Medtronic Vascular, Inc. | $150.51 | 1 | $0 (2019) |
| Allergan Inc. | $106.84 | 2 | $0 (2017) |
| Xeris Pharmaceuticals, Inc. | $85.59 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $84.34 | 4 | $0 (2024) |
| Medtronic, Inc. | $22.06 | 1 | $0 (2021) |
| Philips Electronics North America Corporation | $21.13 | 1 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $19.16 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $397.59 | 21 | Novo Nordisk Inc ($298.60) |
| 2023 | $319.28 | 17 | Novo Nordisk Inc ($319.28) |
| 2022 | $9,775 | 28 | Dexcom, Inc. ($9,401) |
| 2021 | $5,174 | 11 | DEXCOM, INC. ($5,074) |
| 2020 | $55.35 | 3 | Novo Nordisk Inc ($55.35) |
| 2019 | $271.27 | 8 | Medtronic Vascular, Inc. ($150.51) |
| 2018 | $454.22 | 4 | W. L. Gore & Associates, Inc. ($424.52) |
| 2017 | $145.27 | 5 | Allergan Inc. ($106.84) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/14/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $26.71 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/30/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 09/24/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 09/19/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $6.16 | General |
| Category: Obesity | ||||||
| 09/18/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Diabetes | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Respiratory | ||||||
| 08/15/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $5.66 | General |
| 08/08/2024 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Growth Hormone | ||||||
| 07/16/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: Diabetes | ||||||
| 06/04/2024 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Growth Hormone | ||||||
| 05/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: Diabetes | ||||||
| 04/23/2024 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Growth Hormone | ||||||
| 04/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Diabetes | ||||||
| 03/05/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: Diabetes | ||||||
| 02/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Diabetes | ||||||
| 01/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: Diabetes | ||||||
| 12/13/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: Diabetes | ||||||
| 11/30/2023 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Growth Hormone | ||||||
| 10/26/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: Diabetes | ||||||
| 10/10/2023 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Growth Hormone | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 497 | 1,365 | $110,437 | $46,900 |
| 2022 | 13 | 789 | 2,383 | $156,120 | $66,931 |
| 2021 | 16 | 884 | 2,383 | $226,832 | $83,583 |
| 2020 | 19 | 922 | 2,542 | $268,537 | $88,917 |
Total Patients
3,092
Total Services
8,673
Medicare Billing
$286,331
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 108 | 361 | $63,175 | $27,629 | 43.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 110 | 299 | $34,385 | $16,314 | 47.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 47 | 116 | $4,292 | $982.00 | 22.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 106 | 130 | $4,550 | $777.24 | 17.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 20 | 20 | $740.00 | $570.00 | 77.0% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 21 | 21 | $588.00 | $459.90 | 78.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 12 | 12 | $672.00 | $94.68 | 14.1% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 28 | 145 | $725.00 | $51.70 | 7.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 45 | 261 | $1,310 | $21.43 | 1.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 151 | 647 | $75,245 | $35,311 | 46.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 94 | 203 | $35,525 | $18,864 | 53.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 39 | 127 | $9,675 | $3,737 | 38.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 234 | 343 | $12,005 | $1,910 | 15.9% |
| 99307 | Follow-up nursing facility visit per day, typically 10 minutes | Facility | 2022 | 18 | 75 | $5,250 | $1,739 | 33.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 72 | 195 | $6,875 | $1,733 | 25.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 16 | $3,340 | $1,389 | 41.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 14 | 14 | $1,960 | $765.37 | 39.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 26 | 26 | $962.00 | $711.36 | 73.9% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 26 | 26 | $728.00 | $548.34 | 75.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 12 | 14 | $784.00 | $131.76 | 16.8% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 22 | 138 | $740.00 | $50.59 | 6.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 66 | 559 | $3,031 | $42.34 | 1.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 185 | 1,066 | $133,250 | $60,759 | 45.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 51 | 168 | $21,000 | $4,928 | 23.5% |
| 99307 | Subsequent nursing facility visit, typically 10 minutes per day | Facility | 2021 | 22 | 138 | $20,700 | $3,958 | 19.1% |
About Dr. Amit Vora, MD
Dr. Amit Vora, MD is a Internal Medicine healthcare provider based in Hartselle, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1336121458.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amit Vora, MD has received a total of $16,593 in payments from pharmaceutical and medical device companies, with $397.59 received in 2024. These payments were reported across 97 transactions from 12 companies. The most common payment nature is "Compensation for serving as faculty or as a speaker for a medical education program" ($8,426).
As a Medicare-enrolled provider, Vora has provided services to 3,092 Medicare beneficiaries, totaling 8,673 services with total Medicare billing of $286,331. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Hartselle, AL
- Active Since 11/15/2005
- Last Updated 04/01/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1336121458
Products in Payments
- Dexcom G6 Transmitter (Medical Supply) $9,401
- DEXCOM G6 TRANSMITTER (Device) $5,074
- Ozempic (Drug) $511.31
- CARDIOFORM Septal Occluder (Device) $424.52
- Rybelsus (Drug) $398.04
- CoreValve Evolut (Device) $172.57
- Sogroya (Biological) $111.86
- NAMZARIC (Drug) $102.25
- RECORLEV (Drug) $85.59
- FARXIGA (Drug) $70.94
- Norditropin (Drug) $50.91
- Norditropin (Biological) $47.94
- (8874) inCourage (Device) $21.13
- Utibron (Drug) $19.16
- Tresiba (Drug) $18.26
- COLOGUARD (Device) $14.04
- AIRSUPRA (Drug) $13.40
- XIFAXAN (Drug) $12.27
- Wegovy (Drug) $6.16
- LINZESS (Drug) $4.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.